Acelyrin

Acelyrin, clinical trial data, inflammatory diseases, failed trials, ulcerative colitis, phase 3 trial, IPO, stock price

Acelyrin’s lead drug flops in phase 3 trial, wiping out half of its market value

Anika Sharma

Acelyrin, a biotech company based in Los Angeles, has delivered a shocking blow to its investors. Despite successfully raising an ...